LentiGlobin gene therapy for sickle cell on course for filing, says bluebird

It has been an amazing year for patients with sickle cell disease (SCD) with two new drug approvals in recent weeks, and hopes are also building that bluebird bio’s LentiGlobin gene therapy could be filed for approval.